GlassScriptPhysician profile
In Chul An
NPI 1063705135
$8,576.43
in general payments reported to CMS, 2019-2025
36 companies · $1,549 in 2025
The $1,549 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $618 · 2021: $1,123 · 2022: $1,449 · 2023: $1,383 · 2024: $1,711 · 2025: $1,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,557 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,556.97 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,579.72 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $792.79 | 2020-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $611.87 | 2020-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $611.66 | 2019-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $316.84 | 2022-2025 | |
| Gilead Sciences, INC. | $305.87 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $261.05 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $231.07 | 2021-2024 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $229.26 | 2022-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $162.61 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $145.85 | 2019-2024 | Exalt Model D, Captivator II |
| Ferring Pharmaceuticals INC. | $128.12 | 2019-2023 | Rebyota |
| Daiichi Sankyo INC. | $105.87 | 2019-2022 | |
| Ardelyx, INC. | $101.67 | 2022-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $91.98 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $90.69 | 2019-2024 | Suflave, Sutab |
| Pfizer INC. | $88.10 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $83.69 | 2021-2024 | Dificid |
| Qol Medical, LLC | $81.12 | 2019-2024 | Sucraid, Sucraid |
| Celgene Corporation | $79.09 | 2021-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $69.57 | 2024-2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $49.55 | 2022-2024 | Linzess |
| Medtronic, INC. | $47.64 | 2025 | Interstim |
| Aimmune Therapeutics, INC. | $40.09 | 2023-2025 | Zenpep |
| Romark Laboratories, Lc | $37.05 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $32.41 | 2024 | |
| Organon LLC | $32.18 | 2024-2025 | Hadlima, Renflexis |
| Alfasigma USA, INC. | $29.25 | 2020 | |
| Ucb, INC. | $22.79 | 2019 | |
| Amgen INC. | $19.53 | 2022 | |
| Allergan, INC. | $19.42 | 2019 | |
| Vivus LLC | $18.25 | 2022 | |
| Madrigal Pharmaceuticals | $18.16 | 2025 | Rezdiffra |
| Lilly USA, LLC | $17.55 | 2025 | Omvoh |
| Redhill Biopharma INC. | $12.06 | 2020 | |
| Evoke Pharma, INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw In Chul An listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.